Health
USANA Signs Deal with Basketball New Zealand
Becomes Official Nutritional Supplement Supplier of Tall Blacks and Sky Sport Tall Ferns Squads SALT LAKE CITY, June 1, 2022 /PRNewswire/ -- For 30 years USANA, the Cellular Nutrition Company, has been a leader in its industry. With more professional and Olympic athletes trusting USANA with thei...
2022-06-01 02:22
2325
Toku Eyes, Developer of an AI Platform That Accurately Identifies Risk of Heart Attack Using an Eye Image, Expands to The US
With Toku Eyes' artificial intelligence platform, the eye is not only the window to the soul — it is now a window to the state of your health AUCKLAND, New Zealand, May 31, 2022 /PRNewswire/ -- Toku Eyes, the New Zealand -based developer of a multi-modal artificial intelligence platform for instan...
2022-06-01 00:00
2233
QureBio Ltd. to Showcase its Q-1802 Clinical Advances at 2022 ASCO Annual Meetings
SHANGHAI, May 31, 2022 /PRNewswire/ -- QureBio Ltd., a clinical-stage biopharmaceutical company focusing on bi-specific antibodies and other engineered bio-therapeutics for the treatment of cancer, inflammation, and other serious disorders, today announced that its Q-1802 clinical program was se...
2022-05-31 22:30
2101
Paramedic Training VR Nearly Doubles Students' Understanding of Teamwork in Medicine.
The Demonstration Test was Conducted for 663 Students at 14 Vocational Schools. 〜 The effect of VR was Confirmed in In-Hospital Care by Paramedics as its Importance is Increasing under the Revised Paramedic Act〜 TOKYO, May 31, 2022 /PRNewswire/ -- Jolly Good Inc. (based in Chuo-ku, Tokyo, Japan;...
2022-05-31 21:00
1571
I-Mab Announces Completion of Patient Enrollment in Phase III Clinical Trial of Eftansomatropin alfa for Treatment of Pediatric Growth Hormone Deficiency
SHANGHAI and GAITHERSBURG, Md., May 31, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced the completion of patient enrollment in a Phase 3 clinica...
2022-05-31 20:00
1683
Volition Achieves CE Mark for Nu.Q® NETs Test
to aid the detection and evaluation of diseases associated with NETosis AUSTIN, Texas, May 31, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced that its Nu.Q® NETs test has been CE marked for the detection and evaluat...
2022-05-31 20:00
3157
GBM AGILE OPENS TO PAXALISIB IN EUROPE
SYDNEY, May 31, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that the GBM AGILE study in glioblastoma (NCT03970447) has opened recruitment to the paxalisib arm inEurope. University Hospital Zurich...
2022-05-31 19:20
3246
Illuccix® Granted Transitional Pass-Through Payment Status
INDIANAPOLIS, May 31, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announced that its prostate cancer imaging agent Illuccix® (kit for preparation of gallium Ga 68 gozetotide injection) has been granted Transitional Pass-Through Payment Status by the U.S...
2022-05-31 19:00
1267
Latest Results from AENEAS Study of Hansoh Pharma's Ameile® Published in Top International Academic Journal JCO
SHANGHAI, May 31, 2022 /PRNewswire/ -- Recently, the Journal of Clinical Oncology (JCO, IF:44.544), an internationally renowned oncology journal, published an online paper on the AENEAS study of Ameile® (Aumolertinib Mesylate Tablets, an innovative drug developed by Hansoh Pharma), which was led ...
2022-05-31 17:56
752
AffaMed Therapeutics Announces First Patient Dosed in the US Phase 1 Clinical Trial of AM712 in Retinal Disease
SHANGHAI, May 30, 2022 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global clinical-stage biopharmaceutical company dedicated to developing and commercializing transformative pharmaceutical, digital and surgical products, announces that the first patient has been dosed in its US Phase 1 st...
2022-05-31 11:30
1489
Nature Cancer Publishes the Collaborative Study Results by Transcenta and Shanghai Jiao Tong University Scientists
Preclinical Studies on the Potential Application of Transcenta's First-In-Class Gremlin1 Targeting Antibody in the Treatment of Androgen Receptor-Negative/Low Prostate Cancer SUZHOU, China, May 30, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage bio...
2022-05-31 08:08
1361
Weiyun AI & Robotics Group Attended The Annual Meeting of AAO with Its AI SMILE New Breakthough, Shows Its Leading Power in Industrial AI of Dental Medicine
SHANGHAI, May 30, 2022 /PRNewswire/ -- On May 24, 2022, the 122nd Annual Meeting of the American Association of Orthodontists (AAO) came to a successful conclusion inMiami, USA. After two years of online annual meeting, this year, experts and scholars in the field of orthodontics from all over th...
2022-05-30 22:15
1737
The Global Fight Against Monkeypox: Zelixir Biotech Predicts Monkeypox Protein Structures
Abstract: China's biotech company Zelixir Biotech publishes 600+ protein structure predictions for the Monkeypox proteome SHANGHAI, May 30, 2022 /PRNewswire/ -- Zelixir Biotech announces it has predicted more than 600 structures and added functional annotations of proteins from monkeypox virus p...
2022-05-30 18:36
1966
InxMed IN10018 at ASCO 2022 demonstrates robust efficacy in patients with platinum-resistant recurrent ovarian cancer
NANJING, China, May 29, 2022 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology company dedicates on developing innovative therapies targeting stroma microenvironment and drug resistance for hard-to-treat solid tumors, is pleased to announce that the clinical data from an open-label...
2022-05-30 08:10
1851
IASO Biotherapeutics' Equecabtagene Autoleucel, the World's First CAR-T for Treatment of NMOSD, Receives IND Application Acceptance by NMPA
SAN JOSE, Calif., NANJING, China and SHANGHAI, May 28, 2022 /PRNewswire/ -- IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing innovative cell therapies and antibody products, announced today thatChina's National Medic...
2022-05-28 19:33
5165
Jacobio will Present Phase I Clinical Data of KRAS G12C Inhibitor JAB-21822 at the 2022 ASCO Annual Meeting
BEIJING, SHANGHAI and BOSTON, May 27, 2022 /PRNewswire/ -- Jacobio Pharma (1167.HK) is pleased to announce that the phase I clinical data of KRAS G12C inhibitor JAB-21822 will be presented in the form of poster at the upcoming 2022 annual meeting of American Society of Clinical Oncology (ASCO) fr...
2022-05-28 00:22
6136
Asieris to present a study protocol of APL-1202 in combination with BeiGene's tislelizumab as neoadjuvant therapy（NAC）for muscle invasive bladder cancer (MIBC) patients at 2022 ASCO annual meeting
SHANGHAI, May 27, 2022 /PRNewswire/ -- Asieris Pharmaceuticals (688176.SH), a global innovative biopharma company specializing in discovering and developing innovative drugs for the treatment of genitourinary tumors and other major diseases announced that ANTICIPATE Study will be presented at the...
2022-05-27 22:16
2966
ASCO | OriCell Therapeutics Announces Oral Presentation at 2022 ASCO Annual Meeting Detailing Results from Phase I POLARIS Study of OriCAR-017
SHANGHAI, May 27, 2022 /PRNewswire/ -- OriCell Therapeutics Co., Ltd (OriCell), a leading innovative biopharmaceutical company pioneering novel oncology cell therapies for the unmet medical needs in in hematology and oncology, today announced that an abstract detailing data from a Phase I study(P...
2022-05-27 21:49
2592
Dizal to Demonstrate the Strength and Rapid Acceleration of its Clinical Portfolio at ASCO 2022
Sunvozertinib (DZD9008) shows superior efficacy in NSCLC patients harboring EGFR exon 20 insertion mutations after platinum and anti-PD(L)1 treatment failures Golidocitinib (DZD4205) demonstrates enormous potential for peripheral T-cell lymphoma DZD1516 exemplifies full BBB-penetration in patie...
2022-05-27 18:00
1690
ASCO 2022 | Ascentage Pharma Presents Updated Results from Multiple Clinical Studies Demonstrating Rapid Progress in Global Clinical Development
SUZHOU, China, and ROCKVILLE, Md., May 26, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that its seven clinical abstracts selected by the ...
2022-05-27 10:02
2338
Week's Top Stories
Most Reposted
Brankas Launches Integrated APAC Open Banking Compliance Solution with ADVANCE.AI's eKYC Solution
[Picked up by 319 media titles]
2024-11-07 09:00
Going Global: DCITS Embarks on International Expansion at Singapore Fintech Festival
[Picked up by 313 media titles]
2024-11-12 09:00
DKSH Healthcare and Euris Unveil CRM & MCE Platform "ConnectPlus" to Revolutionize APAC Healthcare Distribution
[Picked up by 292 media titles]
2024-11-13 09:00
Sobot Introduces its All-in-One Solution at GITEX Global 2024
[Picked up by 291 media titles]
2024-11-12 11:00
Ubiqconn Technology to Showcase Latest Marine Solutions at the 2024 International WorkBoat Show in New Orleans
[Picked up by 289 media titles]
2024-11-11 21:00
Most Read
Brankas Launches Integrated APAC Open Banking Compliance Solution with ADVANCE.AI's eKYC Solution
2024-11-07 09:00
10151
XtalPi and Sinar Mas Multiartha Launch Strategic Partnership to Revolutionize AI Across Asia-Pacific
2024-11-07 11:34
7509
XTEP's First Mono Store in Malaysia Comes to Puchong
2024-11-07 10:08
6226
